One-year results show “superior” primary patency rate for Eluvia DES compared to bare metal stents

205
Yann Gouëffic presents at VIVA 2021

One-year results presented at Vascular Interventional Advances (VIVA) 2021 (5–7 October, Las Vegas, USA) from the EMINENT trial demonstrated the superiority of the Eluvia drug-eluting stent (DES) system (Boston Scientific) compared to self-expanding bare metal stents for the treatment of patients with peripheral arterial disease (PAD) with superficial femoral artery (SFA) or popliteal artery lesions up to 210mm in length, the principal investigator (PI) said. The study enrolled 775 patients, making it the largest randomised trial of a drug-eluting stent for the treatment of PAD to date, Boston Scientific said in a press release.

In the trial, the Eluvia stent exhibited superiority with a primary patency rate of 85.4% vs. 76.3% with bare metal stents (p=0.0087), data presented by EMINENT study PI Yann Gouëffic, from the Department of Vascular and Endovascular Surgery at Paris Saint-Joseph Hospital, Paris, France, showed.

The analysis also showed a significantly greater rate of sustained clinical improvement without reintervention—83% for patients treated with the Eluvia stent compared to 76.6% for those treated with a bare metal stent (p=0.0450). Further, there was no significant difference in major adverse events or all-cause mortality rates between patients treated with the Eluvia stent and those treated with a bare metal stent through one year.

“I am honoured to have been part of this global study, which adds to the robust body of evidence from the IMPERIAL trial and confirms that the Eluvia stent should be considered the stent of choice for treating SFA and [popliteal] lesions of intermediate length,” said Gouëffic. “The superior primary patency rates and greater rates of clinical improvement without reintervention are reassuring for physicians looking to make clinically-based treatment decisions for their patients and reduce the need for repeat procedures.”


LEAVE A REPLY

Please enter your comment!
Please enter your name here